Zobrazeno 1 - 10
of 4 667
pro vyhledávání: '"Human Epidermal Growth Factor Receptor 2"'
Publikováno v:
Zhongguo aizheng zazhi, Vol 34, Iss 10, Pp 915-930 (2024)
Background and purpose: Human epidermal growth factor receptor 2 (HER2) serves as one of the paramount drivers of breast cancer metastasis, with roughly 20%-30% of breast cancer patients exhibiting high expression of HER2. The expression level of HER
Externí odkaz:
https://doaj.org/article/748144ad3a6d46719701668ff7f284fc
Publikováno v:
Zhongguo linchuang yanjiu, Vol 37, Iss 10, Pp 1494-1498 (2024)
"Objective To analyze multimodal ultrasonic characteristics of human epidermal growth factor receptor 2 (HER-2) positive breast cancer patients in different hormone receptor (HR) expression states, so as to provide a reference for the early diagnosis
Externí odkaz:
https://doaj.org/article/494f58039a07426a80ea5882d7b4e558
Publikováno v:
Open Medicine, Vol 19, Iss 1, Pp 5361-6 (2024)
This study aimed to assess the biodistribution and bioactivity of the affibody molecular probe 99mTc-(HE)3ZHER2:V2, prepared by genetic recombination, and to investigate its potential for targeted human epidermal growth factor receptor 2 (HER2) imagi
Externí odkaz:
https://doaj.org/article/5bb85cdfd20f4bd18d5379f28ddee8b8
Autor:
Yusuke Gokon, Yuka Nakashima, Yusuke Ohki, Takahiro Ogino, Keiichiro Hatoyama, Kenji Shimizu, Toshiaki Kashiwadate, Kazunori Katsura, Takayuki Abe, Koichiro Sato
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-6 (2024)
Abstract Introduction Mutated human epidermal growth factor receptor 2 (HER2) is an oncogene with critical pathogenic roles in breast cancer. HER2-low-positive breast cancer is a recently described subtype. We aimed to explore the clinical and molecu
Externí odkaz:
https://doaj.org/article/9a42d35684fd48a9b0ce4a8be3cd84ac
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background The prognostic value of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) has been extensively studied and verified by the CellSearch® system. Varieties of microfluidic systems have been developed to improve captur
Externí odkaz:
https://doaj.org/article/b73ad06a859b45e080115653b8b18d36
Autor:
Danilo Giffoni de Mello Morais Mata, Mary-Beth Rush, Megan Smith-Uffen, Jawaid Younus, Ana Elisa Lohmann, Maureen Trudeau, Rebecca L. Morgan
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4486-4506 (2024)
Background: Anthracycline-taxane is the standard chemotherapy strategy for treating high-risk early breast cancer despite the potentially life-threatening adverse events caused by anthracyclines. Commonly, the combination of docetaxel and cyclophosph
Externí odkaz:
https://doaj.org/article/61091beb6ad8455eaf7e5d113d0d0827
Autor:
Song Wu, Li Bian, Haibo Wang, Shaohua Zhang, Tao Wang, Zhigang Yu, Jianbin Li, Feng Li, Kun Wang, Zefei Jiang
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-10 (2024)
Abstract Background TCbHP (taxane + carboplatin + trastuzumab + pertuzumab) is the preferred neoadjuvant therapy regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, no consensus exists regarding whether specif
Externí odkaz:
https://doaj.org/article/a30a3b49893548ab977d8c337f316beb
Publikováno v:
口腔疾病防治, Vol 32, Iss 7, Pp 509-516 (2024)
Objective To summarize the clinicopathological characteristics and prognostic factors of salivary duct carcinoma (SDC) patients. Methods This study was reviewed and approved by the Ethics Committee, and informed consent was obtained from the patients
Externí odkaz:
https://doaj.org/article/cb454fbaa5eb4d9b97a4a15a76c9619f
Publikováno v:
Chinese Journal of Lung Cancer, Vol 27, Iss 6, Pp 431-440 (2024)
Lung cancer is the most common malignant tumor and the second most common malignant tumor in terms of mortality in the world. Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. Currently, the first-line standard t
Externí odkaz:
https://doaj.org/article/24e4571a0d854bb09298304cb36521b3
Publikováno v:
Zhongguo quanke yixue, Vol 27, Iss 18, Pp 2287-2294 (2024)
Gastric cancer (GC) is one of the most heterogeneous and aggressive malignant tumors of the digestive system. Traditional chemotherapy drugs and epidermal growth factor receptor 2 (HER2) targeted drugs such as Trastuzumab still have the disadvantages
Externí odkaz:
https://doaj.org/article/db2411e19c794e91b1221e7a9616593c